NEW YORK (GenomeWeb News) – Horizon Discovery and the University of Washington said today that they have entered into a pair of additional licensing agreements in the area of human gene targeting.

The new agreements give Cambridge, UK-based Horizon the exclusive right to commercialize inventions made by UW researcher David Russell, relating to the use of parvoviral vectors in human genome engineering.

In exchange, UW will be granted an undisclosed number of shares in Horizon and will receive ongoing product royalties from licensed products and services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.